Abstract 589: Discovery of NTX-001, a potent Cbl-b inhibitor with antitumor activity in syngeneic models
Fred Csibi-Levin, David Ciccone(Harvard University), Angela V. Toms, Katarzyna Kopycka(Signature Research (United States)), Peter J. Tummino(Intarcia Therapeutics (United States)), Allan M. Jordan(Signature Research (United States)), David L. Laughton(Signature Research (United States)), Silvana Leit, Samantha Garside(Signature Research (United States)), Xiaohua Zhu(Huashan Hospital), Stuart Thomson(Signature Research (United States)), Beth Browning(Ensemble Therapeutics (United States)), Suzanne L. Jacques(Nimbus (Italy)), Christine Loh, Tom Baker(Signature Research (United States)), Simon D’Archivio(Signature Research (United States))
Cited by 1
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
|Biochemistry|2008|550